BioMimetic shares on roller coaster ride ahead of adcomm review; New vaccine helps protect primates against HIV;

 @FierceBiotech: PBM chief says soaring biotech sector will inspire M&A blitz. Article | Follow @FierceBiotech

 @JohnCFierce: Halozyme gets $9M upfront, $74M in milestones from ViroPharma for Cinryze (subcutaneous) pact. Report | Follow @JohnCFierce

> Shares of BioMimetic Therapeutics ($BMTI) went on a roller coaster ride ahead of an FDA advisory committee's review today of its bone regeneration treatment. The stock plunged after investors scanned FDA staffers' comments, noting that some have concerns with the side effects seen in trials. Shares recovered somewhat, though, after some analysts expressed their belief that the Tennessee biotech can win an approval. And some expressed surprise at the tone of the agency's remarks. "All of their products are based on this platelet-derived growth factor protein, and so if there's difficulty with the FDA as a result of safety concerns, it cuts across their entire platform," said Wedbush analyst Greg Wade. Report

> Robert Ring, the former head of Pfizer's autism unit in Groton, has been named vice president of translational research for Autism Speaks. Story

> Cell Biosciences has acquired Brightwell Technologies of Ottawa, Ontario for about $9 million in cash. Release

Pharma News

@FiercePharma: Sanofi eyes cost cuts and deals for vet unit. News | Follow @FiercePharma

> Ranbaxy scrambles to deliver on Nexium supply deal. Piece

> Analysts: Big Pharma likely to dominate biosimilars market. Report

> Stink strikes J&J again, prompting Prezista recall. Item

Vaccines News

> Inovio's cervical dysplasia vax shows Ph1 promise. Report 

> Prevnar-13 effective in adults over 50 in Ph3 trial. Item 

> GAVI Alliance pours $100M into meningitis vaccine. Story 

> FDA okays Sanofi's microinjection flu vaccine. News‎

> Gates leads $23.4M in funding for HIV/AIDS vaccine. Item 

Manufacturing News

> Pet generics: The next frontier. Item 

> Update: Drug shortages business opportunity gains steam. Story 

> Expert provides insight into global labeling challenges. Item

> New GSK CFO eyeing manufacturing, R&D. Report 

> Big 3 distributors hold big pharma survival clues. Article 

> API mischief may underlie drug shortages. News

And Finally...A new vaccine helped protect 13 of 24 monkeys exposed to the primate version of HIV. Researchers say the T-cell stimulating vaccine could help point the way to a vaccine that could help stop  the spread of AIDS. Article

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.